TGF-β Combo Therapy Cuts Mesothelioma Tumor Growth by 70% in Lab Models

A 2026 study published in Scientific Reports has demonstrated that targeting the TGF-β signaling pathway with a combination of inhibitors can significantly reduce mesothelioma tumor growth in laboratory models. The approach cut cell proliferation by up to 70%, a result that could open new avenues for treating a cancer with limited therapeutic options.

What the Study Found

Researchers used three distinct strategies to block TGF-β signaling in malignant pleural mesothelioma cells: small molecule inhibitors, neutralizing antibodies, and gene silencing techniques. When combined, these approaches produced synergistic effects that outperformed any single treatment.

The results across five mesothelioma cell lines, including patient-derived samples, showed consistent suppression. Cell proliferation dropped by 50% to 70%. Invasiveness, a measure of how aggressively cancer cells spread into surrounding tissue, fell by 60%. Cell migration decreased by 40% to 55%.

The team also tested the combinations in 3D tumor spheroids, structures that more closely mimic how tumors grow in the body. The synergy index, a measurement of how well drugs work together, was below 0.7 across multiple combinations, indicating strong cooperative effects.

Why TGF-β Matters in Mesothelioma

TGF-β is a protein that plays a dual role in cancer. In healthy tissue, it helps regulate cell growth. In mesothelioma tumors, it becomes overactive, promoting tumor progression and helping cancer cells evade the immune system.

This immune evasion is particularly relevant for people with mesothelioma. Current immunotherapy treatments work by helping the immune system recognize and attack cancer cells. If TGF-β is suppressing that immune response, blocking it could make immunotherapies more effective.

The findings align with a growing body of research suggesting that combination strategies, rather than single drugs, may be the key to improving outcomes. A separate 2026 study by Ramundo and colleagues in the International Journal of Molecular Sciences independently confirmed that TGF-β combination approaches suppress proliferation and invasiveness in mesothelioma models.

From Lab to Clinic

The study is preclinical, meaning these results come from cell cultures and laboratory models rather than human trials. The path from lab findings to approved treatments typically takes years and involves multiple phases of clinical trials.

However, the results provide a strong rationale for designing clinical trials that test TGF-β inhibitors alongside existing immunotherapy combinations. For people with mesothelioma, the current standard of care, a combination of nivolumab and ipilimumab, extends median survival to roughly 18 months.

Adding TGF-β blockade could potentially improve on those numbers by addressing one of the mechanisms tumors use to resist treatment.

The median survival for pleural mesothelioma with chemotherapy alone remains approximately 12 months. Any approach that can meaningfully extend that timeline while maintaining quality of life represents a significant step forward.

The Broader Research Landscape

This study adds to a period of accelerating mesothelioma research. Multiple clinical trials are exploring new immunotherapy combinations, CAR T-cell therapies, and targeted treatments that exploit specific genetic vulnerabilities in mesothelioma tumors.

Non-occupational asbestos exposure, including secondary exposure through contaminated work clothing and naturally occurring asbestos in soil, continues to drive new cases. Researchers have also noted that genetic factors, including BAP1 mutations, play a larger role in mesothelioma risk than previously understood.